NCT00966160View on ClinicalTrials.gov

CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Acquired Immunodeficiency SyndromeHIV Infections
Interventions
DRUG

Lopinavir/Ritonavir plus Lamivudine/Zidovudine

400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks

DRUG

Efavirenz plus Lamivudine/Zidovudine

600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks

Trial Locations (1)

Unknown

Medical Clinic I and Department of Pharmacology, University of Cologne, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT00966160 - CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes | Biotech Hunter | Biotech Hunter